Hypertension Clinical Trial
— VASALAOfficial title:
Effects of Alpha-linolenic Acid on 24h-ambulatory Mean Arterial Pressure in Untreated High-normal and Stage I Hypertensive Subjects
Rationale: Increased intakes of n-3 long chain polyunsaturated fatty acids eicosapentanoic
acid (EPA) and docosahexaenoic acid (DHA), mainly found in fatty fish, are recommended for
the prevention of coronary heart disease. Alpha-linolenic acid (ALA, C18:3n-3) is the most
common vegetable-oil based n-3 fatty acid. Evidence exists that ALA supplementation can also
have a protective effect on the development on cardiovascular disease, but may exert its
cardio protective effects through different routes. The benefit may (partly) be due to blood
pressure lowering. However, evidence for beneficial effects of ALA on blood pressure is
conflicting. Therefore, we propose to investigate the effect of flaxseed oil, high in ALA,
using a study powered on 24-hour blood pressure, in a population with high normal blood
pressure and mild hypertension.
Objective: To study the effects of flaxseed oil, rich in ALA on 24h-ambulatory mean arterial
pressure (MAP) in men and women with high-normal blood pressure and mild hypertension
compared to high oleic sunflower oil, poor in ALA.
Study design: Using a double blind randomized, placebo-controlled parallel design, subjects
will receive at random daily 10 g of flaxseed oil or a high-oleic acid sunflower oil (HOSF)
as control for twelve weeks, with a run-in period of 14 days in advance.
Study population: 72 men and women, aged 40-70 years, with untreated high-normal blood
pressure and stage I hypertension and a body mass index between 25 and 35 kg/m2 will
participate in the run-in and intervention period. It is estimated that 144 subject have to
be screened to find 72 subjects that will enter the run-in period.
Intervention: During the run-in period, subjects will receive daily 10 g of palm super olein
oil. During the intervention period subjects receive either 10 g of HOSF or flaxseed oil.
All oils are provided in bottles of 5 g, one will be consumed at breakfast or lunch and one
at dinner.
Main study parameters/endpoints: The main study parameter is the change in 24h-ambulatory
mean arterial pressure (MAP)
Status | Completed |
Enrollment | 62 |
Est. completion date | October 2015 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 40 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Quetelet-index between 25-35 kg/m2 - High-normal blood pressure defined as systolic blood pressure between 130-139 mmHg and/or diastolic blood pressure between 85-89 mmHg. Or stage I hypertension defined as systolic blood pressure between 140-159 mmHg and/or diastolic blood pressure between 90-99 mmHg. - Mean serum total cholesterol/HDL cholesterol ratio < 8 - Mean serum triacylglycerol < 4.5 mmol/L - Mean plasma glucose < 7.0 mmol/L Exclusion Criteria: - Unstable body weight (weight gain or loss >2 kg in the past 3 months) - Use of antihypertensive or anticoagulant medication - Indication for treatment with medication according to the Standard for cardiovascular risk management of the Dutch general practitioners community (NHG) - Usage of non-steroidal anti-inflammatory drugs (such as aspirin, ibuprofen, naproxen) and not able or willing to stop taking them from at least 4 weeks prior to the study - Use of medication or a diet known to affect serum lipid or glucose metabolism - Women with expected changes in the use of oral contraceptives or estrogen replacement therapy during the study period - Women lactating, pregnant or intend to become pregnant during study - Active cardiovascular disease like congestive heart failure or recent (<6 months) event (acute myocardial infarction, cerebro vascular accident) - Severe medical conditions that might interfere with the study such as diabetes mellitus, epilepsy, asthma, chronic obstructive pulmonary disease, inflammatory bowel diseases and rheumatoid arthritis - Smoking or recently quit smoking (<1 years) - Abuse of drugs - More than 21 alcohol consumptions per week for men and 14 consumptions for women - Reported intense sporting activities > 10 h/w - Not possible or difficult to venipuncture as evidenced during the screening visits - Use of an investigational product within the previous 30 days - Not willing to stop the consumption of vitamin supplements, fish oil capsules or products rich in plant stanol or sterol esters 3 weeks before the start of the study - Not willing to give up being a blood donor (or having donated blood) from 8 weeks before the start of the study and during the study |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastricht University Medical Center | Maastricht | Limburg |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center | Unilever R&D |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pulse wave velocity (PWV) | PWV will be determined by extending data from standard brachial artery blood pressure measurements | Baseline and end of intervention period (week 2 and 14) | No |
Other | Retinal microvasculature | Measured as AV-ratio and vessel diameter from digitized analogue fundus photographs | Baseline and end of intervention period (week 2 and 14) | No |
Other | Fasting and postprandial lipid and glucose metabolism | Postprandial glucose at time point 15,30,45,60,90,120,180,240 minutes Postprandial lipids at time point 60, 120, 180, 240 minutes | Every visit (week 1,2,8,14) Postprandial in subset of n=20 per group | No |
Other | Fasting and postprandial serum biomarkers for low-grade systemic inflammation (hsCRP, IL-6) and endothelial function (sICAM-1, VCAM-1, MCP-1 and sE-Selectin) | Every visit (week 1,2,8,14) Postprandial in subset of n=20 per group at time point 60, 120, 240 minutes | No | |
Primary | 24h-ambulatory mean arterial pressure (MAP) | Ambulatory blood pressure measurements will be performed using an automated blood pressure device with 15-minute intervals during the day and 30-minute intervals during the night. | Baseline and end of intervention period (week 2 and 14) | No |
Secondary | Postprandial flow mediated dilatation (FMD) | The brachial artery FMD will be measured in a subset (n=20 per group) of the study population. FMD will be measured before and 2 hours after a fat load. | End of intervention period (week 14) | No |
Secondary | Night, day and early morning 24h-ambulatory MAP, SBP and DBP | Ambulatory blood pressure measurements will be performed using an automated blood pressure device with 15-minute intervals during the day and 30-minute intervals during the night. | Baseline and end of intervention (week 2 and 14) | No |
Secondary | Systolic, diastolic and MAP office blood pressure | Each visit blood pressure will be measured in four-fold with 1-minute interval (the first measurement will be discarded and the last three measurement will be averaged) using a calibrated device. | Measured every visit (week 1,2,8,14) | No |
Secondary | The fatty-acid profile of plasma phospholipids | measured in fasting plasma samples | Baseline and end of intervention period (week 2 and 14) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |